F
Francesca Ricci
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 166
Citations - 4322
Francesca Ricci is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Mesenchymal stem cell & Protein kinase B. The author has an hindex of 33, co-authored 166 publications receiving 3687 citations.
Papers
More filters
Journal ArticleDOI
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy.
Alberto M. Martelli,Giovanna Tabellini,Francesca Ricci,Camilla Evangelisti,Francesca Chiarini,Roberta Bortul,James A. McCubrey,Francesco A. Manzoli +7 more
Journal Article
ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.
Francesca Ricci,Sergio Bernasconi,Luca Porcu,Eugenio Erba,Nicolò Panini,Robert Fruscio,Federica Sina,Torri,Massimo Broggini,Giovanna Damia +9 more
TL;DR: The data suggest that neither ALDH enzymatic activity nor CD133 expression provide additional predictive/prognostic information in ovarian cancer patients.
Journal ArticleDOI
ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
Alessandra Trojani,Marco Montillo,Michele Nichelatti,Alessandra Tedeschi,Chiara Colombo,Silvio Veronese,Maria Angela Mura,Francesca Ricci,Barbara Scarpati,Anna Colosimo,Milena Lodola,Enrica Morra +11 more
TL;DR: It is assessed that IgVh mutational status, ZAP-70 protein and 6q- are powerful prognostic markers and 11q deletion was the strongest predictor of disease progression in B-CLL.
Journal ArticleDOI
The CD47 pathway is deregulated in human immune thrombocytopenia
Lucia Catani,Daria Sollazzo,Francesca Ricci,Nicola Polverelli,Francesca Palandri,Michele Baccarani,Nicola Vianelli,Roberto M. Lemoli +7 more
TL;DR: The results demonstrate that the CD47 pathway in ITP patients abnormally modulates platelet homeostasis.
Journal ArticleDOI
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Armando Santoro,Rita Mazza,Alessandro Pulsoni,Alessandro Re,Maurizio Bonfichi,Vittorio Ruggero Zilioli,Manuela Zanni,Francesco Merli,Antonella Anastasia,Stefano Luminari,Giorgia Annechini,Manuel Gotti,Annalisa Peli,Anna Marina Liberati,Nicola Di Renzo,Luca Castagna,Laura Giordano,Francesca Ricci,Carmelo Carlo-Stella +18 more
TL;DR: The long-term efficacy data, the benefits for both relapsed and refractory patients, and the excellent safety profile provide a strong rationale for further development of the BEGEV regimen.